|Bid||0.00 x 900|
|Ask||0.00 x 1100|
|Day's Range||191.64 - 193.37|
|52 Week Range||158.67 - 202.21|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||188.33|
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Almirall, S.A. Paris, August 11, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Almirall, S.A. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
AbbVie stock broke out in April and the pharmaceutical company just wrapped its acquisition of Allergan. Further, AbbVie is collaborating on a coronavirus drug. Is AbbVie stock a buy now?
TORONTO , June 17, 2020 /CNW/ - NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave") (SPOR.CN) (0XM2.F) (TRMND), an investment issuer focused on emerging sectors including the psychedelic sector, is pleased to announce that it has welcomed Dr. Carolyn Myers , Ph.D. to provide business strategy and business development consulting services to the Company. Dr. Carolyn Myers is an accomplished senior executive with extensive experience creating, growing, and leading health care businesses.